Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Vanda Pharmaceuticals Inc. (VNDA : NSDQ)
 
 • Company Description   
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial.

Number of Employees: 203

 
 • Price / Volume Information   
Yesterday's Closing Price: $4.86 Daily Weekly Monthly
20 Day Moving Average: 347,436 shares
Shares Outstanding: 58.93 (millions)
Market Capitalization: $286.42 (millions)
Beta: 0.68
52 Week High: $6.37
52 Week Low: $3.81
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 4.29% 1.16%
12 Week 11.21% -3.59%
Year To Date 1.46% -4.14%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2200 PENNSYLVANIA AVENUE NW SUITE 300E
-
WASHINGTON,DC 20037
USA
ph: 202-734-3400
fax: 202-296-1450
pr@vandapharma.com http://www.vandapharma.com
 
 • General Corporate Information   
Officers
Mihael H. Polymeropoulos - Chief Executive Officer; Chairman and President
Kevin Moran - Chief Financial Officer
Richard W. Dugan - Director
Anne Sempowski Ward - Director
Phaedra Chrousos - Director

Peer Information
Vanda Pharmaceuticals Inc. (CORR.)
Vanda Pharmaceuticals Inc. (RSPI)
Vanda Pharmaceuticals Inc. (CGXP)
Vanda Pharmaceuticals Inc. (BGEN)
Vanda Pharmaceuticals Inc. (GTBP)
Vanda Pharmaceuticals Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 921659108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 07/30/25
Share - Related Items
Shares Outstanding: 58.93
Most Recent Split Date: (:1)
Beta: 0.68
Market Capitalization: $286.42 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.31 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.49 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/30/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.56
Price/Cash Flow: -
Price / Sales: 1.42
EPS Growth
vs. Year Ago Period: -614.29%
vs. Previous Quarter: -525.00%
Sales Growth
vs. Year Ago Period: 5.43%
vs. Previous Quarter: -5.91%
ROE
06/30/25 - -
03/31/25 - -8.30
12/31/24 - -3.49
ROA
06/30/25 - -
03/31/25 - -6.85
12/31/24 - -2.90
Current Ratio
06/30/25 - -
03/31/25 - 3.93
12/31/24 - 4.39
Quick Ratio
06/30/25 - -
03/31/25 - 3.91
12/31/24 - 4.37
Operating Margin
06/30/25 - -
03/31/25 - -21.98
12/31/24 - -9.51
Net Margin
06/30/25 - -
03/31/25 - -21.98
12/31/24 - -9.51
Pre-Tax Margin
06/30/25 - -
03/31/25 - -27.63
12/31/24 - -11.53
Book Value
06/30/25 - -
03/31/25 - 8.68
12/31/24 - 9.24
Inventory Turnover
06/30/25 - -
03/31/25 - 6.77
12/31/24 - 7.17
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©